Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Accumulated Expenses (2019 - 2025)

C4 Therapeutics' Accumulated Expenses history spans 7 years, with the latest figure at $13.3 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 31.24% year-over-year to $13.3 million; the TTM value through Dec 2025 reached $13.3 million, down 31.24%, while the annual FY2025 figure was $13.3 million, 31.24% down from the prior year.
  • Accumulated Expenses reached $13.3 million in Q4 2025 per CCCC's latest filing, up from $11.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $20.6 million in Q4 2023 to a low of $1.4 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $13.5 million, with a median of $13.6 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 529.94% in 2022, then crashed 33.03% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $13.6 million in 2021, then surged by 45.3% to $19.8 million in 2022, then rose by 4.36% to $20.6 million in 2023, then fell by 6.14% to $19.4 million in 2024, then plummeted by 31.24% to $13.3 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Accumulated Expenses are $13.3 million (Q4 2025), $11.3 million (Q3 2025), and $13.6 million (Q2 2025).